Evidence map›Paper›PMID 40655424›Full record

ArticleBio-protocol2025

Visualization of the Evolution and Transmission of Circulating Vaccine-Derived Poliovirus (cVDPV) Outbreaks in the African Region.

Collins D Owuor, Brook Tesfaye, Arthur Yannick Doungmo Wakem, Sakma Kabore, Caroline Obianuju Ikeonu, Mariette Egbonoumi Fifatin Glitho Epse Doussoh, Priscilla Epse Mosoke Bobimwoh Sigala, Idris Ibrahim Ibrahim, Abdullateef Jimoh, Idah Ndumba and 13 more

Abstract read
In one paragraph

Article in Bio-protocol, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Collins D OwuorPolio Eradication Program, Office of the Regional Director, World Health Organization, Regional Office for Africa, Brazzaville, Republic of the Congo.
Brook TesfayePolio Eradication Program, Office of the Regional Director, World Health Organization, Regional Office for Africa, Brazzaville, Republic of the Congo.
Arthur Yannick Doungmo WakemPolio Eradication Program, Office of the Regional Director, World Health Organization, Regional Office for Africa, Brazzaville, Republic of the Congo.
Sakma KaborePolio Eradication Program, Office of the Regional Director, World Health Organization, Regional Office for Africa, Brazzaville, Republic of the Congo.
Caroline Obianuju IkeonuPolio Eradication Program, Office of the Regional Director, World Health Organization, Regional Office for Africa, Brazzaville, Republic of the Congo.
Mariette Egbonoumi Fifatin Glitho Epse DoussohPolio Eradication Program, Office of the Regional Director, World Health Organization, Regional Office for Africa, Brazzaville, Republic of the Congo.
Priscilla Epse Mosoke Bobimwoh SigalaPolio Eradication Program, Office of the Regional Director, World Health Organization, Regional Office for Africa, Brazzaville, Republic of the Congo.
Idris Ibrahim IbrahimPolio Eradication Program, Office of the Regional Director, World Health Organization, Regional Office for Africa, Brazzaville, Republic of the Congo.
Abdullateef JimohPolio Eradication Program, Office of the Regional Director, World Health Organization, Regional Office for Africa, Brazzaville, Republic of the Congo.
Idah NdumbaPolio Eradication Program, Office of the Regional Director, World Health Organization, Regional Office for Africa, Brazzaville, Republic of the Congo.
Jermaine KhumaloPolio Eradication Program, Office of the Regional Director, World Health Organization, Regional Office for Africa, Brazzaville, Republic of the Congo.
David O OviaesuPolio Eradication Program, Office of the Regional Director, World Health Organization, Regional Office for Africa, Brazzaville, Republic of the Congo.
Cheroigin KipchirchirPolio Eradication Program, Office of the Regional Director, World Health Organization, Regional Office for Africa, Brazzaville, Republic of the Congo.
Carolyne GathenjiPolio Eradication Program, Office of the Regional Director, World Health Organization, Regional Office for Africa, Brazzaville, Republic of the Congo.
John KiptererPolio Eradication Program, Office of the Regional Director, World Health Organization, Regional Office for Africa, Brazzaville, Republic of the Congo.
Kebba TourayPolio Eradication Program, Office of the Regional Director, World Health Organization, Regional Office for Africa, Brazzaville, Republic of the Congo.
Hamisu AbdullahiPolio Eradication Program, Office of the Regional Director, World Health Organization, Regional Office for Africa, Brazzaville, Republic of the Congo.
Kathleen RankinGates Foundation, Seattle, WA, USA.
Ousmane M DiopPolio Eradication Program, World Health Organization, Geneva, Switzerland.
Julius E ChiaPolio Eradication Program, Office of the Regional Director, World Health Organization, Regional Office for Africa, Brazzaville, Republic of the Congo.
Ndoutabe ModjiromPolio Eradication Program, Office of the Regional Director, World Health Organization, Regional Office for Africa, Brazzaville, Republic of the Congo.
Jamal A AhmedPolio Eradication Program, World Health Organization, Geneva, Switzerland.
Anfumbom K W KfutwahPolio Eradication Program, Office of the Regional Director, World Health Organization, Regional Office for Africa, Brazzaville, Republic of the Congo.

Funding

World Health Organization 001
6 · The paper itself

Abstract

Since the creation of the Global Polio Eradication Initiative (GPEI) in 1988, significant progress has been made toward attaining a poliovirus-free world. This has resulted in the eradication of wild poliovirus (WPV) serotypes two (WPV2) and three (WPV3) and limited transmission of serotype one (WPV1) in Pakistan and Afghanistan. However, the increased emergence of circulating vaccine-derived poliovirus (cVDPV) and the continued circulation of WPV1, although limited to two countries, pose a continuous threat of international spread of poliovirus. These challenges highlight the need to further strengthen surveillance and outbreak responses, particularly in the African Region (AFRO). Phylogeographic visualization tools may provide insights into changes in poliovirus epidemiology, which can in turn guide the implementation of more strategic and effective supplementary immunization activities and improved outbreak response and surveillance. We created a comprehensive protocol for the phylogeographic analysis of polioviruses using Nextstrain, a powerful open-source tool for real-time interactive visualization of virus sequencing data. It is expected that this protocol will support poliovirus elimination strategies in AFRO and contribute significantly to global eradication strategies. These tools have been utilized for other pathogens of public health importance, for example, SARS-CoV-2, human influenza, Ebola, and Mpox, among others, through real-time tracking of pathogen evolution (https://nextstrain.org), harnessing the scientific and public health potential of pathogen genome data. Key features • Employs Nextstrain (https://nextstrain.org), which is an open-source tool for real-time interactive visualization of genome sequencing datasets. • First comprehensive protocol for the phylogeographic analysis of poliovirus sequences collected from countries in the World Health Organization (WHO) African Region (AFRO). • Phylogeographic visualization may provide insights into changes in poliovirus epidemiology, which can in turn guide the implementation of more strategic and effective vaccination campaigns. • This protocol can be deployed locally on a personal computer or on a Microsoft Azure cloud server for high throughput.

Indexed as

African Region (AFRO)cVDPVphylogeographyPoliovirusVP1 gene

Identifiers

PMID40655424
PMCPMC12245628

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.